The potential therapeutic value of targeting PANoptosis in inflammatory diseases has also been recently assessed against severe COVID-19 given that SARS-CoV-2 increases RIPK1 activation and ZBP-1 expression to promote viral spread (133–135). The gene discussed is ZBP1; the disease is COVID-19.